Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2021-04-22 / Ther Apher Dial 2021 Apr;MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2021-04-21 / Oncol Lett 2021 Jun;21(6):482Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
/in Curcuma, International Publications /von 2021-04-12 / Front Oncol 2021;11:660712Curcumin and cancer biology: Focusing regulatory effects in different signalling pathways
/in Curcuma, International Publications /von 2021-04-09 / Phytother Res 2021 Apr;Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2021-03-30 / Int J Med Sci 2021;18(11):2294-2302Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-03-29 / Front Immunol 2021;12:641307Curcumin encapsulation in nanostructures for cancer therapy: a 10-year overview
/in Curcuma, International Publications /von 2021-03-26 / Int J Pharm 2021 Mar;:120534Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2021-03-17 / Mol Clin Oncol 2021 May;14(5):103Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review
/in Glioblastoma, Hyperthermia, International Publications /von 2021-03-13 / J Neurooncol 2021 May;152(3):419-428
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells